Volume 14 Number 11/12 November/December 2013

Guide to HIV and HCV coinfection (November 2013)

44th Union World Conference on Lung Health, 30 October – 3 November 2013, Paris

Preventing and treating TB in children – more baby steps

14th European AIDS Conference (EACS), 16-19 October 2013, Brussels

Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study

GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections

Cenicriviroc: 48 week results compared to efavirenz

Approaches to once-daily raltegravir: new formulation likely to require food

DSMB stops boosted atazanavir monotherapy study due to virological failure

Recreational drug use is common in HIV positive gay men and is extensive in a significant minority

Caution against prolonged use of bisphosphonates in patients with mild-moderate fracture risk

Osteoporosis triples risk of later fracture in 1000-person US HIV group

Bone turnover marker changes early in ART predict bone loss after 96 week

Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison

Classic risk factors, but not HIV, linked to arterial stiffness in middle-aged

Elvitegravir approved in EU: data on food and drug interactions

ViiV file 572-trii fixed dose combination in the US: positive opinion to approve dolutegravir in the EU

Obama increases US contribution to Global Fund to $5 billion over three years

HIV struggle in South Africa undermined by medicine stockouts and mismanagement

European guidelines launched at EACS (2013)

Paediatric guidelines on the prevention and treatment of OIs (November 2013)

US HIV guidelines update information on integrase inhibitors (Oct 2013)

Efavirenz is associated with higher suicide risk in meta-analysis of four ACTG studies

EU recommends approval of sofosbuvir for HCV

Compassionate use of declatasvir with sofosbuvir for people in urgent need of HCV treatment

The little blue pill that can stop HIV: PROUD study enrolling gay men in the UK

Dual HIV infection in long term nonprogressor elite controllers

Online journals

Volume 14 Number 11/12 November/December 2013 PDF

Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)

Volume 14 Number 9/10 September/October 2013

CROI website still blocked

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September 2013, Denver

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Good safety profile with long-acting integrase inhibitor GSK744

TAF comparable to TDF in once-daily pill for ART-naive: 48-week results

Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

High prices for antiretrovirals in middle-income countries outside Africa

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US

NHS England approves four-in-one Stribild (Quad) for limited use

Dolutegravir approved in the US

ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK

From sky high to CHAI* – what needs to be done about dolutegravir pricing?

Pharmacokinetics of etravirine with once-daily and twice-daily dosing

UK pledges £1 billion for Global Fund

France pledges $1.4 billion for Global Fund

UNAIDS reports new HIV infections are reduced by one-third compared to 2001

Longitudinal changes in weight, lean body mass and bone mineral density in first-line combinations: ACTG 5205 substudy

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

Activists call EU failure to approve delaminid for MDR tuberculosis due to limited data both “myopic and disappointing”

Circulating memory T follicular helper cells correlate with the development of broadly neutralising antibody responses against HIV

HIV self testing to become legal in the UK from April 2014

Agreement to develop long-acting rilpivirine as PrEP

Use of ART at baseline by treatment naïve patients in HPTN-052

UK to lift ban on HIV positive health workers who are on ART with undetectable viral load

CID supplement on HCV and injecting drug users: free online issue

Volume 14 Number 9/10 September/October 2013 PDF

Volume 14 Number 7/8 July/August 2013 PDF

Volume 14 Number 7/8 July/August 2013

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

Post navigation